Sandoz Group AG - Asset Resilience Ratio
Sandoz Group AG (SDZ) has an Asset Resilience Ratio of 7.89% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sandoz Group AG current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Sandoz Group AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Sandoz Group AG total assets.
Liquid Assets Composition Over Time
This chart breaks down Sandoz Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Sandoz Group AG carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF1.74 Billion | 7.89% |
| Short-term Investments | CHF0.00 | 0% |
| Total Liquid Assets | CHF1.74 Billion | 7.89% |
Asset Resilience Insights
- Limited Liquidity: Sandoz Group AG maintains only 7.89% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Sandoz Group AG Industry Peers by Asset Resilience Ratio
Compare Sandoz Group AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Sandoz Group AG (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Sandoz Group AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.89% | CHF1.74 Billion ≈ $2.20 Billion |
CHF22.03 Billion ≈ $27.85 Billion |
+1.91pp |
| 2024-12-31 | 5.98% | CHF1.19 Billion ≈ $1.51 Billion |
CHF19.91 Billion ≈ $25.17 Billion |
+1.18pp |
| 2023-12-31 | 4.80% | CHF933.39 Million ≈ $1.18 Billion |
CHF19.43 Billion ≈ $24.56 Billion |
-- |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more